Humira (adalimumab) and Entyvio (vedolizumab) are brand-name drugs. They’re both prescribed for Crohn’s disease and ulcerative colitis in certain people. This article explains the main similarities ...
Entyvio (vedolizumab) is a prescription drug that doctors use to treat moderate or severe ulcerative colitis and Crohn’s disease. It may take up to 14 weeks for Entyvio to work effectively. However, ...
More common side effects of Entyvio (vedolizumab) include headache, fatigue, nausea, fever, and infection, such as the common cold. Entyvio may cause long-term side effects, which may last even after ...
Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...
Ulcerative colitis and Crohn’s disease are types of inflammatory bowel disease (IBD) that cause irritation and inflammation in the gastrointestinal tract (GI tract). The immune system attacks the GI ...
− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...
Spyre Therapeutics’ stock is up nearly 30% after its ulcerative colitis (UC) candidate has demonstrated competitive remission-prompting potential during a Phase II study, leading analysts to tout the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results